Transactions
29
Insider / Arcutis Biotherapeutics, Inc.
Burnett Patrick
See Remarks at Arcutis Biotherapeutics, Inc.
- Ticker
- ARQT
- First filing on record
- November 5, 2025
- Latest trade on record
- August 19, 2026
- SEC filings
- EDGAR ↗
Burnett Patrick, See Remarks at Arcutis Biotherapeutics, Inc., has disclosed 29 transactions in ARQT since November 5, 2025: 0 purchases (0 open-market buys) and 18 sales, worth about $2.2M at the reported prices. The latest was filed August 21, 2026, 2 days after the trade; 1 filing was late against the 2-business-day Form 4 deadline.
Open-market buys
0
Sales
18
Avg. disclosure lag
46.6d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months Burnett Patrick made no purchases and 18 sales worth $2.0M, plus 10 other transactions. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
Burnett Patrick has traded 1 stock on record; the largest by dollars is ARQT.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
1 of 12 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| S | Open-market sale | 18 | 77,737 | $2.0M |
| M | Option exercise or conversion | 8 | 87,500 | $159K |
| A | Grant or award | 3 | 123,750 | — |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 17 | 0 | 11 · $1.1M |
| 2025 | 11 | 0 | 7 · $956K |
| 2022 | 1 | 0 | 0 |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| ARQT | Sell S | August 19, 2026 | August 21, 2026 | 2d | 1,697 | $27 | $46K | Form 4 ↗ | ||
| ARQT | Option / conversion M | August 12, 2026 | August 13, 2026 | 1d | 6,700 | — | — | derivative | Form 4 ↗ | |
| ARQT | Option / conversion M | August 11, 2026 | August 13, 2026 | 2d | 8,300 | — | — | derivative | Form 4 ↗ | |
| ARQT | Sell S | August 12, 2026 | August 13, 2026 | 1d | 6,700 | $26 | $175K | Form 4 ↗ | ||
| ARQT | Option / conversion M | August 12, 2026 | August 13, 2026 | 1d | 6,700 | $4 | $24K | Form 4 ↗ | ||
| ARQT | Sell S | August 11, 2026 | August 13, 2026 | 2d | 8,300 | $27 | $220K | Form 4 ↗ | ||
| ARQT | Option / conversion M | August 11, 2026 | August 13, 2026 | 2d | 8,300 | $4 | $30K | Form 4 ↗ | ||
| ARQT | Sell S | August 3, 2026 | August 5, 2026 | 2d | 955 | $26 | $25K | 10b5-1 plan | Form 4 ↗ | |
| ARQT | Sell S | May 11, 2026 | May 13, 2026 | 2d | 222 | $21 | $4,673 | 10b5-1 plan | Form 4 ↗ | |
| ARQT | Sell S | May 4, 2026 | May 6, 2026 | 2d | 684 | $24 | $16K | 10b5-1 plan | Form 4 ↗ | |
| ARQT | Other A | February 27, 2026 | March 3, 2026 | 4d | 77,000 | — | — | 10b5-1 planderivative | Form 4 ↗ | |
| ARQT | Sell S | March 2, 2026 | March 3, 2026 | 1d | 181 | $26 | $4,690 | 10b5-1 plan | Form 4 ↗ | |
| ARQT | Sell S | March 2, 2026 | March 3, 2026 | 1d | 6,106 | $25 | $154K | 10b5-1 plan | Form 4 ↗ | |
| ARQT | Other A | February 27, 2026 | March 3, 2026 | 4d | 30,000 | — | — | 10b5-1 plan | Form 4 ↗ | |
| ARQT | Other A | August 18, 2022 | March 3, 2026 | 1293d | 16,750 | — | — | late10b5-1 plan | Form 4 ↗ | |
| ARQT | Sell S | February 4, 2026 | February 4, 2026 | 0d | 9,794 | $26 | $253K | 10b5-1 plan | Form 4 ↗ | |
| ARQT | Sell S | February 2, 2026 | February 4, 2026 | 2d | 3,675 | $25 | $94K | 10b5-1 plan | Form 4 ↗ | |
| ARQT | Sell S | January 5, 2026 | January 7, 2026 | 2d | 2,490 | $29 | $72K | 10b5-1 plan | Form 4 ↗ | |
| ARQT | Sell S | December 31, 2025 | January 2, 2026 | 2d | 1,156 | $29 | $34K | 10b5-1 plan | Form 4 ↗ | |
| ARQT | Sell S | December 31, 2025 | January 2, 2026 | 2d | 541 | $29 | $16K | 10b5-1 plan | Form 4 ↗ | |
| ARQT | Option / conversion M | December 15, 2025 | December 17, 2025 | 2d | 11,500 | — | — | 10b5-1 planderivative | Form 4 ↗ | |
| ARQT | Sell S | December 15, 2025 | December 17, 2025 | 2d | 11,500 | $29 | $333K | 10b5-1 plan | Form 4 ↗ | |
| ARQT | Option / conversion M | December 15, 2025 | December 17, 2025 | 2d | 11,500 | $4 | $42K | 10b5-1 plan | Form 4 ↗ | |
| ARQT | Option / conversion M | November 6, 2025 | November 10, 2025 | 4d | 17,250 | — | — | 10b5-1 planderivative | Form 4 ↗ | |
| ARQT | Sell S | November 6, 2025 | November 10, 2025 | 4d | 17,250 | $24 | $417K | 10b5-1 plan | Form 4 ↗ | |
| ARQT | Option / conversion M | November 6, 2025 | November 10, 2025 | 4d | 17,250 | $4 | $63K | 10b5-1 plan | Form 4 ↗ | |
| ARQT | Sell S | November 5, 2025 | November 5, 2025 | 0d | 3,864 | $24 | $92K | 10b5-1 plan | Form 4 ↗ | |
| ARQT | Sell S | November 3, 2025 | November 5, 2025 | 2d | 15 | $25 | $381 | 10b5-1 plan | Form 4 ↗ | |
| ARQT | Sell S | November 3, 2025 | November 5, 2025 | 2d | 2,607 | $25 | $64K | 10b5-1 plan | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| August 21, 2026 | Form 4 | 0001628280-26-058420 | 1 | published | EDGAR ↗ |
| August 13, 2026 | Form 4 | 0001628280-26-056898 | 6 | published | EDGAR ↗ |
| August 5, 2026 | Form 4 | 0001628280-26-053755 | 1 | published | EDGAR ↗ |
| May 13, 2026 | Form 4 | 0001741987-26-000004 | 1 | published | EDGAR ↗ |
| May 6, 2026 | Form 4 | 0001741987-26-000002 | 1 | published | EDGAR ↗ |
| March 3, 2026 | Form 4 | 0001628280-26-014324 | 5 | published | EDGAR ↗ |
| February 4, 2026 | Form 4 | 0001628280-26-005571 | 2 | published | EDGAR ↗ |
| January 7, 2026 | Form 4 | 0001628280-26-001241 | 1 | published | EDGAR ↗ |
| January 2, 2026 | Form 4 | 0001628280-26-000209 | 2 | published | EDGAR ↗ |
| December 17, 2025 | Form 4 | 0001741987-25-000010 | 3 | published | EDGAR ↗ |
| November 10, 2025 | Form 4 | 0001741987-25-000008 | 3 | published | EDGAR ↗ |
| November 5, 2025 | Form 4 | 0001741987-25-000005 | 3 | published | EDGAR ↗ |
Other insiders at Arcutis Biotherapeutics, Inc.
- Welgus Howard G. Director 49 rows
- Matsuda Masaru See Remarks 20 rows
- Watanabe Todd See Remarks 15 rows
- Leonard Keith R Director 13 rows
- Curran Terrie Director 11 rows
- Edwards Larry Todd See Remarks 8 rows
- Krishnamohan Neha Director 8 rows
- LIN SUE-JEAN Director 8 rows
- Vairavan Latha SVP Chief Financial Officer 8 rows
- Gilbert Halley E Director 7 rows
Everyone on file, with contracts and lobbying under the company's name: Arcutis Biotherapeutics, Inc..
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Rule 10b5-1 trading plans The plan must be set up when the insider has no important non-public information.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 12 | 29 | November 5, 2025 | August 21, 2026 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.